If VAXINIA and Azer-Cel can expand to other solid and liquid market then it will be massive but the revenue for cholangiocarcinoma and DLBCL is big because they are rare disease so the treatment cost is more expensive. Like I said, the CR was good as IMU only need a quarter of funding as assurance since they know the clinical trial updates will further positive in 3 months time. CVI will be converting at 10c in 3 months time if they don't do this now.
IMU Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)